Lepodisiran sodium

Highest phase reached
Phase 3
www.ebi.ac.uk
Drug type
Oligonucleotide
www.ebi.ac.uk

Listing at source
Listed
Highest phase reached
Phase 3
www.ebi.ac.uk

Drug type
Oligonucleotide
www.ebi.ac.uk
Drug name
Lepodisiran sodium
www.ebi.ac.uk

  • duplex of all p ambo 4 de hydroxymethyl 4 hydroxymethylphosphinoyl methoxy 2 o methylthiouridylyl 2 deoxy 2 fluorothioadenylyl 3 5 2 deoxy 2 fluorothioguanylyl 3 5 2 deoxy 2 fluoroadenylyl 3 5 2 deoxy 2 fluorouridylyl 3 5 2 o methylguanylyl 3 5 2 deoxy 2 fluoroadenylyl 3 5 2 o methylcytidylyl 3 5 2 o methylcytidylyl 3 5 2 deoxy 2 fluoroadenylyl 3 5 2 o methyladenylyl 3 5 2 o methylguanylyl 3 5 2 o methylcytidylyl 3 5 2 deoxy 2 fluorouridylyl 3 5 2 o methyluridylyl 3 5 2 o methylguanylyl 3 5 2 o methylguanylyl 3 5 2 o methylcytidylyl 3 5 2 o methyladenylyl 3 5 2 o methylthioadenylyl 3 5 2 o methylthioguanylyl 3 5 2 o methylguanosine and all p ambo 2 o methylthiouridylyl 5 3 2 o methyluridylyl 5 3 2 o methylguanylyl 5 3 2 o methylcytidylyl 5 3 2 o methylcytidylyl 5 3 2 o methyladenylyl 5 3 2 o methyladenylyl 5 3 2 deoxy 2 fluoroguanylyl 5 3 2 deoxy 2 fluorocytidylyl 5 3 2 deoxy 2 fluorouridylyl 5 3 2 deoxy 2 fluorouridylyl 5 3 2 o methylguanylyl 5 3 2 o methylguanylyl 5 3 2 o methyluridylyl 5 3 2 o methylcytidylyl 5 3 2 o methyladenylyl 5 3 2 o methyluridylyl 5 3 2 o methylcytidylyl 5 3 2 o methyluridylyl 5 3 2 o methyladenylyl 5 3 2 o methylguanylyl 5 3 2 o methylcytidylyl 5 3 2 o methyladenylyl 5 3 2 o methylguanylyl 5 3 2 o methylcytidylyl 5 3 2 o methylcytidylyl 5 3 2 o methylguanylyl 5 3 2 2 5 2 acetamido 2 deoxy b d galactopyranosyl oxy pentanamido ethoxy ethoxy methyl adenylyl 5 3 2 2 5 2 acetamido 2 deoxy b d galactopyranosyl oxy pentanamido ethoxy ethoxy methyl adenylyl 5 3 2 2 5 2 acetamido 2 deoxy b d galactopyranosyl oxy pentanamido ethoxy ethoxy methyl adenylyl 5 3 2 o methylguanylyl 5 3 2 o methylguanylyl 5 3 2 o methylcytidylyl 5 3 2 o methyluridylyl 5 3 2 o methylguanylyl 5 3 2 o methylcytosine sodium salt 1 57
  • duplex of all-P-ambo-4′-de(hydroxymethyl)-4′-[(hydroxymethylphosphinoyl)methoxy]-2′-O-methylthiouridylyl-2′-deoxy-2′-fluorothioadenylyl-(3'→5')-2′-deoxy-2′-fluorothioguanylyl-(3'→5')-2′-deoxy-2′-fluoroadenylyl-(3'→5')-2′-deoxy-2′-fluorouridylyl-(3'→5')-2′-O-methylguanylyl-(3'→5')-2′-deoxy-2′-fluoroadenylyl-(3'→5')-2′-O-methylcytidylyl-(3'→5')-2′-O-methylcytidylyl-(3'→5')-2′-deoxy-2′-fluoroadenylyl-(3'→5')-2′-O-methyladenylyl-(3'→5')-2′-O-methylguanylyl-(3'→5')-2′-O-methylcytidylyl-(3'→5')-2′-deoxy-2′-fluorouridylyl-(3'→5')-2′-O-methyluridylyl-(3'→5')-2′-O-methylguanylyl-(3'→5')-2′-O-methylguanylyl-(3'→5')-2′-O-methylcytidylyl-(3'→5')-2′-O-methyladenylyl-(3'→5')-2′-O-methylthioadenylyl-(3'→5')-2′-O-methylthioguanylyl-(3'→5')-2′-O-methylguanosine and all-P-ambo-2′-O-methylthiouridylyl-(5′→3′)-2′-O-methyluridylyl-(5′→3′)-2′-O-methylguanylyl-(5′→3′)-2′-O-methylcytidylyl-(5′→3′)-2′-O-methylcytidylyl-(5′→3′)-2′-O-methyladenylyl-(5′→3′)-2′-O-methyladenylyl-(5′→3′)-2′-deoxy-2′-fluoroguanylyl-(5′→3′)-2′-deoxy-2′-fluorocytidylyl-(5′→3′)-2′-deoxy-2′-fluorouridylyl-(5′→3′)-2′-deoxy-2′-fluorouridylyl-(5′→3′)-2′-O-methylguanylyl-(5′→3′)-2′-O-methylguanylyl-(5′→3′)-2′-O-methyluridylyl-(5′→3′)-2′-O-methylcytidylyl-(5′→3′)-2′-O-methyladenylyl-(5′→3′)-2′-O-methyluridylyl-(5′→3′)-2′-O-methylcytidylyl-(5′→3′)-2′-O-methyluridylyl-(5′→3′)-2′-O-methyladenylyl-(5′→3′)-2′-O-methylguanylyl-(5′→3′)-2′-O-methylcytidylyl-(5′→3′)-2′-O-methyladenylyl-(5′→3′)-2′-O-methylguanylyl-(5′→3′)-2′-O-methylcytidylyl-(5′→3′)-2′-O-methylcytidylyl-(5′→3′)-2′-O-methylguanylyl-(5′→3′)-{2-[2-{5-[(2-acetamido-2-deoxy-b-D-galactopyranosyl)oxy]pentanamido}ethoxy)ethoxy]methyl}adenylyl-(5′→3′)-{2-[2-{5-[(2-acetamido-2-deoxy-b-D-galactopyranosyl)oxy]pentanamido}ethoxy)ethoxy]methyl}adenylyl-(5′→3′)-{2-[2-{5-[(2-acetamido-2-deoxy-b-D-galactopyranosyl)oxy]pentanamido}ethoxy)ethoxy]methyl}adenylyl-(5′→3′)-2′-O-methylguanylyl-(5′→3′)-2′-O-methylguanylyl-(5′→3′)-2′-O-methylcytidylyl-(5′→3′)-2′-O-methyluridylyl-(5′→3′)-2′-O-methylguanylyl-(5′→3′)-2′-O-methylcytosine—sodium salt (1:57)
  • lepodisiran sodium
  • Lepodisiran sodium
  • LEPODISIRAN SODIUM [USAN]
  • lepodisiran sodium usan
  • ly 3819469 sodium
  • LY-3819469 SODIUM
  • ly3819469 sodium
  • LY3819469 SODIUM
  • rna 4 de hydroxymethyl 4 hydroxymethoxyphosphinyl methoxy um sp 2 deoxy 2 fluoro a sp 2 deoxy 2 fluoro g sp 2 deoxy 2 fluoro a 2 deoxy 2 fluoro u gm 2 deoxy 2 fluoro a cm cm 2 deoxy 2 fluoro a am gm cm 2 deoxy 2 fluoro u um gm gm cm am am sp gm sp gm sodium salt complex with rna um sp um gm cm cm am am 2 deoxy 2 fluoro g 2 deoxy 2 fluoro c 2 deoxy 2 fluoro u 2 deoxy 2 fluoro u gm gm um cm am um cm um am gm cm am gm cm cm gm 2 o 2 2 5 2 acetylamino 2 deoxy β d galactopyranosyl oxy 1 oxopentyl amino ethoxy ethoxy methyl a 2 o 2 2 5 2 acetylamino 2 deoxy β d galactopyranosyl oxy 1 oxopentyl amino ethoxy ethoxy methyl a 2 o 2 2 5 2 acetylamino 2 deoxy β d galactopyranosyl oxy 1 oxopentyl amino ethoxy ethoxy methyl a gm gm cm um gm cm sodium salt 1 22 1 35
  • RNA, ([4′-de(hydroxymethyl)-4′-[(hydroxymethoxyphosphinyl)methoxy]]Um-sp-(2′-deoxy-2′-fluoro)A-sp-(2′-deoxy-2′-fluoro)G-sp-(2′-deoxy-2′-fluoro)A-(2′-deoxy-2′-fluoro)U-Gm-(2′-deoxy-2′-fluoro)A-Cm-Cm-(2′-deoxy-2′-fluoro)A-Am-Gm-Cm-(2′-deoxy-2′-fluoro)U-Um-Gm-Gm-Cm-Am-Am-sp-Gm-sp-Gm), sodium salt, complex with RNA (Um-sp-Um-Gm-Cm-Cm-Am-Am-(2′-deoxy-2′-fluoro)G-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)U-Gm-Gm-Um-Cm-Am-Um-Cm-Um-Am-Gm-Cm-Am-Gm-Cm-Cm-Gm-[2′-O-[[2-[2-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]ethoxy]ethoxy]methyl]]A-[2′-O-[[2-[2-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]ethoxy]ethoxy]methyl]]A-[2′-O-[[2-[2-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]ethoxy]ethoxy]methyl]]A-Gm-Gm-Cm-Um-Gm-Cm) sodium salt (1:22:1:35)

CAS registry numbers
  • 2766131-24-0
ChEMBL ID
CHEMBL6068446
www.ebi.ac.uk
FDA ingredient codes (UNII)
  • 7DR6F86F5U

First in class
No
Orphan designation
No

Investigated indications

  • Condition
    Cardiovascular Diseases
    Highest recorded phase
    1
    Condition identifier
    EFO:0000319
    Subject identifier
    D002318

  • Condition identifier
    EFO_0000319
  • Condition identifier
    MONDO_0004995

Prodrug
No
Chirality
Single enantiomer
Inorganic
No
Natural product
No

Sequences

  • Component
    Sequence
    Type
    Nucleic Acid
    Sequence
    (5'-3') U=U-G-C-A-A-G-C-U-U-G-G-U-C-A-U-C-U-A-G-C-A-G-C-C-G (3'-5') G=G=A-A-C-G-U-U-C-G-A-A-C-C-A-G-U-A=G=A=U-C-G-U-C-G-G 57NA+

Related records

Trials (1)

In development for (1)